

**RECEIVED  
CENTRAL FAX CENTER****FEB 27 2006**

Practitioner's Docket No. 117163.00077

**PATENT****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Carsten Momma, Andreas Becker, Robert Schmiedl, and Bernd Heublein

Application No.: 10/630,355

Group No.: 3738

Filed: 07/30/2003

Examiner: Brian E. Pellegrino

For: ENDOVASCULAR IMPLANT FOR THE INJECTION OF AN ACTIVE SUBSTANCE INTO  
THE MEDIA OF A BLOOD VESSEL**Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450****AMENDMENT TRANSMITTAL**

1. Transmitted herewith is an amendment for this application.

**STATUS**

2. Applicant is other than a small entity.

**CERTIFICATION UNDER 37 C.F.R. §§ 1.8(a) and 1.10\****(When using Express Mail, the Express Mail label number is mandatory;  
Express Mail certification is optional.)*

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**37 C.F.R. § 1.8(a)**☐ with sufficient postage as first class mail.**37 C.F.R. § 1.10\***☐ as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_ (mandatory)**TRANSMISSION**☒ facsimile transmitted to the Patent and Trademark Office, (571) 273 - 8300.  
Signature

Georgann Testa

---

(type or print name of person certifying)Date: February 27, 2006

\* Only the date of filing (§ 1.6) will be the date used in a patent term adjustment calculation, although the date on any certificate of mailing or transmission under § 1.8 continues to be taken into account in determining timeliness. See § 1.703(f). Consider "Express Mail Post Office to Addressee" (§ 1.10) or facsimile transmission (§ 1.6(d)) for the reply to be accorded the earliest possible filing date for patent term adjustment calculations.

Amendment Transmittal--page 1 of 2

Akron - 106194.1

**RECEIVED  
CENTRAL FAX CENTER**

**FEB 27 2006**

**EXTENSION OF TERM**

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

**FEE FOR CLAIMS**

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

	(Col. 1) CLAIMS REMAINING AFTER AMENDMENT	(Col. 2) HIGHEST NO. PREVIOUSLY PAID FOR	(Col. 3) PRESENT EXTRA	OTHER THAN A SMALL ENTITY					ADDIT. FEE
TOTAL	28	-	32	=	0	x	\$	50.00	= \$ 0.00
INDEP.	1	-	3	=	0	x	\$	200.00	= \$ 0.00
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						+	\$	180.0	= \$ 0.00
TOTAL ADDIT. FEE								\$	0.00

No additional fee for claims is required.


**FEE DEFICIENCY**

5. If an additional extension and/or fee is required, charge Account No. 15-0450.

If an additional fee for claims is required, charge Account No. 15-0450.

Date: 27 February 2006

Reg. No.: 42,451  
Tel. No.: 330-864-5550  
Customer No.: 021324

  
Signature of Practitioner  
John J. Cunniff  
Hahn Loeser & Parks LLP  
One GoJo Plaza  
Suite 300  
Akron, OH 44311-1076

Amendment Transmittal--page 2 of 2

Akron - 106194.1

Ser. No. 10/630,355  
Response to Office Action of 11/30/05  
Atty Docket No.: 117163.00077

- 1 -

**FEB 27 2006****IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

<b>Inventor:</b>	Momma, et al	<b>Examiner:</b>	Brian E. Pellegrino
<b>Ser. No.</b>	10/630,355	<b>Group Art Unit:</b>	3738
<b>Title:</b>	<b>ENDOVASCULAR IMPLANT FOR THE INJECTION OF AN ACTIVE SUBSTANCE INTO THE MEDIA OF A BLOOD VESSEL</b>		
<b>Filed:</b>	July 30, 2003	<b>Date:</b>	February 27, 2006

**RESPONSE AND AMENDMENT AFTER FINAL OFFICE ACTION**  
**(37 CFR 1.116)**

In response to the final Office Action mailed 30 November 2005, please amend the above-identified application as follows:

AMENDMENTS TO THE SPECIFICATION – none;  
AMENDMENTS TO THE CLAIMS – begin on page 2.  
AMENDMENTS TO THE DRAWINGS - none.  
REMARKS/ARGUMENTS – begin on page 7.

AKR - 106171.1